

Jennifer Dailey-Provost proposes the following substitute bill:

Veterans PTSD Clinical Research Amendments

2026 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Jennifer Dailey-Provost

Senate Sponsor: Kirk A. Cullimore

LONG TITLE

General Description:

This bill addresses psychedelic-assisted therapy for certain veterans.

Highlighted Provisions:

This bill:

- ▶ authorizes the Huntsman Mental Health Institute (Huntsman) to conduct a clinical study on the safety and feasibility of psychedelic-assisted therapy for veterans with treatment-resistant post-traumatic stress disorder;
- ▶ permits Huntsman to accept donations to fund the clinical study;
- ▶ requires Huntsman to begin the clinical study if legislative appropriations and donations combined are equal to or exceed an amount sufficient to begin the study;
- ▶ requires reporting to the Health and Human Services Interim Committee;
- ▶ provides a sunset date for the provisions related to the clinical study;
- ▶ defines terms; and
- ▶ makes technical and conforming changes.

Money Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:

AMENDS:

63I-1-226, as last amended by Laws of Utah 2025, Chapters 47, 277 and 366

ENACTS:

26B-7-126, Utah Code Annotated 1953

Be it enacted by the Legislature of the state of Utah:

29 Section 1. Section **26B-7-126** is enacted to read:

30 **26B-7-126 . Psychedelic-assisted therapy for veterans clinical study -- Funding --**

31 **Reports.**

32 (1) As used in this section:

33 (a) "Clinical study" means the safety and feasibility study authorized in this section.

34 (b) "Controlled substance" means the same as that term is defined in Section 58-37-2.

35 (c) "Eligible veteran" means a veteran who has treatment-resistant PTSD.

36 (d) "FDA" means the United States Food and Drug Administration.

37 (e) "Huntsman Mental Health Institute" means the mental health and substance use
38 treatment institute within the University of Utah.

39 (f) "Investigational drug" means an investigational new drug that the FDA has
40 authorized for human subjects research under 21 C.F.R. Part 312.

41 (g) "Investigational new drug" means the same as that term is defined in 21 C.F.R. Sec.
42 312.3.

43 (h) "Psychedelic drug" means a controlled substance that is an investigational drug and
44 has a hallucinogenic effect on the central nervous system, including:

45 (i) 3,4-Methylenedioxymethamphetamine (MDMA);

46 (ii) 5-methoxy-N,N-dimethyltryptamine; or

47 (iii) Psilocybin.

48 (i) "Psychedelic-assisted therapy" means an intervention where:

49 (i) a psychedelic drug is administered to an individual with treatment-resistant PTSD
50 in a controlled clinical setting; and

51 (ii) a qualified therapist delivers manualized, trauma-informed preparatory and
52 integrative psychotherapy to the individual before and after administration of the
53 psychedelic drug.

54 (j) "PTSD" means post-traumatic stress disorder.

55 (k) "Treatment-resistant PTSD" means a clinical diagnosis of PTSD with documented
56 inadequate response to one or more evidence-based treatments for PTSD.

57 (2) Subject to Subsections (4) and (5), within appropriations from the Legislature for this
58 purpose and any gifts, grants, or donations the Huntsman Mental Health Institute
59 receives under Subsection (3), the Huntsman Mental Health Institute shall conduct a
60 clinical study to research the safety and feasibility of psychedelic-assisted therapy for
61 the treatment of treatment-resistant PTSD in eligible veterans.

62 (3) The Huntsman Mental Health Institute may accept gifts, grants, and donations of money

- 63 to fund the clinical study.
- 64 (4)(a) The Huntsman Mental Health Institute shall begin the clinical study no later than
65 January 1, 2027, if the total amount of legislative appropriations and gifts, grants, or
66 donations the Huntsman Mental Health Institute receives under Subsection (3)
67 reaches an amount that is equal to or exceeds an amount the Huntsman Mental Health
68 Institute determines is sufficient to begin the clinical study.
- 69 (b) If the Huntsman Mental Health Institute begins the clinical study on or before
70 January 1, 2027, the Huntsman Mental Health Institute may:
- 71 (i) accept gifts, grants, or donations after January 1, 2027; and
72 (ii) use amounts received under Subsection (3), or appropriated by the Legislature for
73 this purpose, after January 1, 2027, to continue funding the clinical study.
- 74 (5) If the Huntsman Mental Health Institute does not begin the study on or before January
75 1, 2027, because the total amounts accepted and appropriated under this section are
76 insufficient to begin the clinical study, the Huntsman Mental Health Institute:
- 77 (a) may continue to accept gifts, grants, or donations, after January 1, 2027;
78 (b) shall begin the clinical study when the total amount of legislative appropriations and
79 gifts, grants, or donations reaches an amount that is equal to or exceeds an amount
80 the Huntsman Mental Health Institute determines is sufficient to begin the clinical
81 study; and
- 82 (c) may use amounts received under Subsection (3), or appropriated by the Legislature
83 for this purpose, after January 1, 2027, to continue funding the clinical study.
- 84 (6) The Huntsman Mental Health Institute shall return to a donor any unused gifts, grants,
85 or donations the Huntsman Mental Health Institute received under Subsection (3) on or
86 before July 1, 2032.
- 87 (7) Before beginning the clinical study, the Huntsman Mental Health Institute shall:
- 88 (a) comply with state and federal regulations, including by:
- 89 (i) ensuring that the clinical study will be conducted under an FDA investigational
90 new drug application;
- 91 (ii) maintaining a United States Drug Enforcement Agency Schedule I research
92 registration and any required state controlled substance registration; and
- 93 (iii) obtaining Institutional Review Board approval for the clinical study;
- 94 (b) have a clinical study protocol that includes:
- 95 (i) the study design, inclusion and exclusion criteria, objectives and endpoints,
96 eligible veteran visit schedule, and schedule of follow-up assessments;

- 97 (ii) informed consent procedures and participant safeguards; and
98 (iii) data security and privacy protections, including for personal information;
99 (c) have a drug administration plan for the clinical study that includes:
100 (i) the investigational drug product description, source, formulation, route of
101 administration, and dosing regimen;
102 (ii) a clinical staffing model and monitoring procedures for the administration of the
103 investigational drug;
104 (iii) discharge criteria and transportation procedures for participants after
105 psychedelic-assisted therapy; and
106 (iv) procedures for the storage, handling, chain of custody, and disposal of controlled
107 substances, and an accountability plan for violations of the procedures;
108 (d) have a safety monitoring and risk management plan for the clinical study that
109 includes:
110 (i) medical and psychiatric screening procedures;
111 (ii) on-site emergency response procedures;
112 (iii) adverse event and serious adverse event capture and reporting timelines; and
113 (iv) predefined rules for pausing or stopping the clinical study; and
114 (e) have a fidelity plan for the clinical study that includes:
115 (i) a psychotherapy manual that describes preparatory sessions, therapeutic support
116 boundaries for the administration of the investigational drug during
117 psychedelic-assisted therapy sessions, and integrative sessions;
118 (ii) therapist licensure and qualification requirements;
119 (iii) a training, supervision, and fidelity monitoring plan; and
120 (iv) ethical safeguards and a participant complaint and grievance process.
121 (8)(a) The Huntsman Mental Health Institute shall:
122 (i) report to the Health and Human Services Interim Committee, upon request of the
123 committee, on the progress of the clinical study; and
124 (ii) submit a final written report of the clinical study to the Health and Human
125 Services Interim Committee on or before the committee's first November meeting
126 after the date on which the Huntsman Mental Health Institute concludes the
127 clinical study.
128 (b) The report described in Subsection (8)(a)(ii) shall include:
129 (i) safety and feasibility outcomes for the use of psychedelic-assisted therapy for the
130 treatment of treatment-resistant PTSD in eligible veterans; and

- 131 (ii) secondary or exploratory clinical outcomes of the clinical study.
- 132 Section 2. Section **63I-1-226** is amended to read:
- 133 **63I-1-226 . Repeal dates: Titles 26 through 26B.**
- 134 (1) Subsection 26B-1-204(2)(g), regarding the Youth Electronic Cigarette, Marijuana, and
- 135 Other Drug Prevention Committee, is repealed July 1, 2030.
- 136 (2) Subsection 26B-1-204(2)(h), regarding the Primary Care Grant Committee, is repealed
- 137 July 1, 2035.
- 138 (3) Section 26B-1-315, Medicaid ACA Fund, is repealed July 1, 2034.
- 139 (4) Section 26B-1-318, Brain and Spinal Cord Injury Fund, is repealed July 1, 2029.
- 140 (5) Section 26B-1-402, Rare Disease Advisory Council Grant Program -- Creation --
- 141 Reporting, is repealed July 1, 2026.
- 142 (6) Section 26B-1-409, Utah Digital Health Service Commission -- Creation -- Membership
- 143 -- Duties, is repealed July 1, 2025.
- 144 (7) Section 26B-1-410, Primary Care Grant Committee, is repealed July 1, 2035.
- 145 (8) Section 26B-1-417, Brain and Spinal Cord Injury Advisory Committee -- Membership
- 146 -- Duties, is repealed July 1, 2029.
- 147 (9) Section 26B-1-422, Early Childhood Utah Advisory Council -- Creation --
- 148 Compensation -- Duties, is repealed July 1, 2029.
- 149 (10) Section 26B-1-425, Utah Health Workforce Advisory Council -- Creation and
- 150 membership, is repealed July 1, 2027.
- 151 (11) Section 26B-1-428, Youth Electronic Cigarette, Marijuana, and Other Drug Prevention
- 152 Committee and Program -- Creation -- Membership -- Duties, is repealed July 1, 2030.
- 153 (12) Section 26B-1-430, Coordinating Council for Persons with Disabilities -- Policy
- 154 regarding services to individuals with disabilities -- Creation -- Membership --
- 155 Expenses, is repealed July 1, 2027.
- 156 (13) Section 26B-1-432, Newborn Hearing Screening Committee, is repealed July 1, 2026.
- 157 (14) Section 26B-2-407, Drinking water quality in child care centers, is repealed July 1,
- 158 2027.
- 159 (15) Subsection 26B-3-107(9), regarding reimbursement for dental hygienists, is repealed
- 160 July 1, 2028.
- 161 (16) Section 26B-3-136, Children's Health Care Coverage Program, is repealed July 1, 2025.
- 162 (17) Section 26B-3-137, Reimbursement for diabetes prevention program, is repealed June
- 163 30, 2027.
- 164 (18) Subsection 26B-3-213(2)(b), regarding consultation with the Behavioral Health Crisis

- 165 Response Committee, is repealed December 31, 2026.
- 166 (19) Section 26B-3-302, DUR Board -- Creation and membership -- Expenses, is repealed
167 July 1, 2027.
- 168 (20) Section 26B-3-303, DUR Board -- Responsibilities, is repealed July 1, 2027.
- 169 (21) Section 26B-3-304, Confidentiality of records, is repealed July 1, 2027.
- 170 (22) Section 26B-3-305, Drug prior approval program, is repealed July 1, 2027.
- 171 (23) Section 26B-3-306, Advisory committees, is repealed July 1, 2027.
- 172 (24) Section 26B-3-307, Retrospective and prospective DUR, is repealed July 1, 2027.
- 173 (25) Section 26B-3-308, Penalties, is repealed July 1, 2027.
- 174 (26) Section 26B-3-309, Immunity, is repealed July 1, 2027.
- 175 (27) Title 26B, Chapter 3, Part 5, Inpatient Hospital Assessment, is repealed July 1, 2034.
- 176 (28) Title 26B, Chapter 3, Part 6, Medicaid Expansion Hospital Assessment, is repealed
177 July 1, 2034.
- 178 (29) Title 26B, Chapter 3, Part 7, Hospital Provider Assessment, is repealed July 1, 2028.
- 179 (30) Section 26B-3-910, Alternative eligibility -- Report -- Alternative Eligibility
180 Expendable Revenue Fund, is repealed July 1, 2028.
- 181 (31) Section 26B-4-710, Rural residency training program, is repealed July 1, 2025.
- 182 (32) Subsection 26B-5-112(1)(b), regarding consultation with the Behavioral Health Crisis
183 Response Committee, is repealed December 31, 2026.
- 184 (33) Subsection 26B-5-112(5)(b), regarding consultation with the Behavioral Health Crisis
185 Response Committee, is repealed December 31, 2026.
- 186 (34) Section 26B-5-112.5, Mobile Crisis Outreach Team Grant Program, is repealed
187 December 31, 2026.
- 188 (35) Section 26B-5-114, Behavioral Health Receiving Center Grant Program, is repealed
189 December 31, 2026.
- 190 (36) Section 26B-5-118, Collaborative care grant program, is repealed December 31, 2024.
- 191 (37) Section 26B-5-120, Virtual crisis outreach team grant program, is repealed December
192 31, 2026.
- 193 (38) Subsection 26B-5-609(1)(a), regarding the Behavioral Health Crisis Response
194 Committee, is repealed December 31, 2026.
- 195 (39) Subsection 26B-5-609(3)(b), regarding the Behavioral Health Crisis Response
196 Committee, is repealed December 31, 2026.
- 197 (40) Subsection 26B-5-610(1)(b), regarding the Behavioral Health Crisis Response
198 Committee, is repealed December 31, 2026.

- 199 (41) Subsection 26B-5-610(2)(b)(ii), regarding the Behavioral Health Crisis Response
200 Committee, is repealed December 31, 2026.
- 201 (42) Section 26B-5-612, Integrated behavioral health care grant programs, is repealed
202 December 31, 2025.
- 203 (43) Title 26B, Chapter 5, Part 7, Utah Behavioral Health Commission, is repealed July 1,
204 2029.
- 205 (44) Subsection 26B-5-704(2)(a), regarding the Behavioral Health Crisis Response
206 Committee, is repealed December 31, 2026.
- 207 (45) Title 26B, Chapter 5, Part 8, Utah Substance Use and Mental Health Advisory
208 Committee, is repealed January 1, 2033.
- 209 (46) Section 26B-7-119, Hepatitis C Outreach Pilot Program, is repealed July 1, 2028.
- 210 (47) Section 26B-7-122, Communication Habits to reduce Adolescent Threats Pilot
211 Program, is repealed July 1, 2029.
- 212 (48) Section 26B-7-123, Report on CHAT campaign, is repealed July 1, 2029.
- 213 (49) Section 26B-7-126, Psychedelic-assisted therapy for veterans clinical study -- Funding
214 -- Reports, is repealed July 1, 2032.
- 215 [~~49~~] (50) Title 26B, Chapter 8, Part 5, Utah Health Data Authority, is repealed July 1,
216 2026.
- 217 Section 3. **Effective Date.**
- 218 This bill takes effect on May 6, 2026.